(firstQuint)Phase I Safety and Immunogenicity of FP-02.

2 in Chronic Hepatitis B.

 This study evaluates the safety and immunogenicity of FP-02.

2, a new therapeutic Hepatitis B vaccine, administered as an add-on therapy to entecavir or tenofovir.

 HBeAg-negative subjects will be randomized to receive low or high dose vaccine, in the presence or absence of IC31(R) adjuvant, or to receive placebo or IC31(R) adjuvant alone.

.

 Phase I Safety and Immunogenicity of FP-02.

2 in Chronic Hepatitis B@highlight

This study evaluates the safety and immunogenicity of FP-02.

2, a new therapeutic Hepatitis B vaccine, administered as an add-on therapy to entecavir or tenofovir.

